{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:47:46Z","timestamp":1792054066270,"version":"4.4.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118538","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:07:50Z","timestamp":1791846470000},"page":"118538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["Role of the RAGE signaling pathway in myocardial ischemia\/reperfusion injury"],"prefix":"10.1016","volume":"254","author":[{"given":"Peng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.118538_b0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/eurheartj\/ehae803","article-title":"Type 2 myocardial infarction: challenges in diagnosis and treatment","volume":"46","author":"Chapman","year":"2025","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12872-023-03231-w","article-title":"The global prevalence of myocardial infarction: a systematic review and meta-analysis","volume":"23","author":"Salari","year":"2023","journal-title":"BMC Cardiovasc. Disord."},{"issue":"14","key":"10.1016\/j.bcp.2026.118538_b0015","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.bcp.2026.118538_b0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","article-title":"Myocardial ischaemia-reperfusion injury and cardioprotection in perspective","volume":"17","author":"Heusch","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"22","key":"10.1016\/j.bcp.2026.118538_b0025","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.jacc.2024.02.056","article-title":"Reperfusion injury in patients with acute myocardial infarction: JACC scientific statement","volume":"83","author":"Welt","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2026.118538_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102884","article-title":"Mitochondria in acute myocardial infarction and cardioprotection","volume":"57","author":"Ramachandra","year":"2020","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.bcp.2026.118538_b0035","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.apsb.2020.03.004","article-title":"Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia-reperfusion injury","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"21","key":"10.1016\/j.bcp.2026.118538_b0040","doi-asserted-by":"crossref","first-page":"14998","DOI":"10.1016\/S0021-9258(18)42138-2","article-title":"Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins","volume":"267","author":"Neeper","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.bcp.2026.118538_b0045","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1016\/S0021-9258(18)42137-0","article-title":"Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface","volume":"267","author":"Schmidt","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118538_b0050","doi-asserted-by":"crossref","unstructured":"G. Yepuri, S.N. Hasan, V. Kumar, M.B. Manigrasso, G. Theophall, A. Shekhtman, A.M. Schmidt, R. Ramasamy, Mechanistic underpinnings of AGEs-RAGE via DIAPH1 in ischemic, diabetic, and failing hearts, American journal of physiology. Heart and circulatory physiology (2025).","DOI":"10.1152\/ajpheart.00685.2024"},{"issue":"11","key":"10.1016\/j.bcp.2026.118538_b0055","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","article-title":"Understanding RAGE, the receptor for advanced glycation end products","volume":"83","author":"Bierhaus","year":"2005","journal-title":"J. Mol. Med. (Berl)"},{"issue":"4","key":"10.1016\/j.bcp.2026.118538_b0060","doi-asserted-by":"crossref","first-page":"H1823","DOI":"10.1152\/ajpheart.01210.2007","article-title":"RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model","volume":"294","author":"Aleshin","year":"2008","journal-title":"Am. J. Physiol. Heart Circulatory Physiol."},{"issue":"25","key":"10.1016\/j.bcp.2026.118538_b0065","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1161\/CIRCULATIONAHA.108.769331","article-title":"High-mobility group box-1 in ischemia-reperfusion injury of the heart","volume":"117","author":"Andrassy","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2026.118538_b0070","article-title":"Increased cardiac expression of the receptor for advanced glycation end products is associated with myocardial apoptosis in patients post coronary artery bypass grafting and in mice following myocardial infarction","volume":"134","author":"Tsoporis","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1515\/hsz-2023-0134","article-title":"HMGB1-RAGE axis contributes to myocardial ischemia\/reperfusion injury via regulation of cardiomyocyte autophagy and apoptosis in diabetic mice","volume":"405","author":"He","year":"2024","journal-title":"Biol. Chem."},{"issue":"621","key":"10.1016\/j.bcp.2026.118538_b0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf7084","article-title":"Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice","volume":"13","author":"Manigrasso","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0085","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2337\/db07-0326","article-title":"RAGE and modulation of ischemic injury in the diabetic myocardium","volume":"57","author":"Bucciarelli","year":"2008","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.bcp.2026.118538_b0090","doi-asserted-by":"crossref","first-page":"11923","DOI":"10.3390\/ijms130911923","article-title":"A soluble receptor for advanced glycation end-products inhibits hypoxia\/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway","volume":"13","author":"Guo","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2026.118538_b0095","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/CIRCULATIONAHA.105.575993","article-title":"Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury","volume":"113","author":"Bucciarelli","year":"2006","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0100","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1089\/ars.2010.3764","article-title":"Advanced glycation end products accelerate ischemia\/reperfusion injury through receptor of advanced end product\/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells","volume":"15","author":"Liu","year":"2011","journal-title":"Antioxid. Redox Signal."},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0105","first-page":"E841","article-title":"The alternative crosstalk between RAGE and nitrative thioredoxin inactivation during diabetic myocardial ischemia-reperfusion injury, American journal of physiology","volume":"303","author":"Liu","year":"2012","journal-title":"Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.amjms.2024.08.001","article-title":"Soluble RAGE attenuates myocardial I\/R injury by suppressing interleukin-6","volume":"369","author":"Zhang","year":"2025","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0115","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00395-012-0250-z","article-title":"S100A8\/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-kappaB signaling","volume":"107","author":"Volz","year":"2012","journal-title":"Basic Res. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118538_b0120","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00395-010-0114-3","article-title":"HMGB1: the missing link between diabetes mellitus and heart failure","volume":"105","author":"Volz","year":"2010","journal-title":"Basic Res. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0360","first-page":"300","article-title":"Endothelial RAGE exacerbates acute postischaemic cardiac inflammation","volume":"116","author":"Ziegler","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2026.118538_b0225","article-title":"Remote ischemic postconditioning protects against myocardial ischemia-reperfusion injury by inhibition of the RAGE-HMGB1 pathway","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res. Int."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2026.118538_b0345","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s10495-022-01724-1","article-title":"Integrin\u03b23 mediates the protective effects of soluble receptor for advanced glycation end-products during myocardial ischemia\/reperfusion through AKT\/STAT3 signaling pathway","volume":"27","author":"Han","year":"2022","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.bcp.2026.118538_b0485","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3760\/cma.j.issn.0366-6999.2010.05.017","article-title":"Intra-coronary administration of soluble receptor for advanced glycation end-products attenuates cardiac remodeling with decreased myocardial transforming growth factor-beta1 expression and fibrosis in minipigs with ischemia-reperfusion injury","volume":"123","author":"Lu","year":"2010","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0505","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41374-018-0102-z","article-title":"Interferon-\u03b3 mediates the protective effects of soluble receptor for advanced glycation end-product in myocardial ischemia\/reperfusion","volume":"99","author":"Dang","year":"2019","journal-title":"Lab. Invest.; J. Techn. Methods Pathol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118538_b0265","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.jtcvs.2018.09.043","article-title":"The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1-receptor for advanced glycation end products-Toll-like receptor 9 pathway","volume":"157","author":"Tian","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"5","key":"10.1016\/j.bcp.2026.118538_b0385","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00018-022-04307-0","article-title":"Soluble RAGE attenuates myocardial I\/R injuries via FoxO3-Bnip3 pathway","volume":"79","author":"Zhang","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0370","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1038\/s41467-023-42521-x","article-title":"DIAPH1-MFN2 interaction regulates mitochondria-SR\/ER contact and modulates ischemic\/hypoxic stress","volume":"14","author":"Yepuri","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133414","article-title":"All-trans retinoic acid ameliorates myocardial ischemia\/reperfusion injury by reducing cardiomyocyte apoptosis","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bcp.2026.118538_b0190","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/eci.12789","article-title":"ADAM10 modulates calcitriol-regulated RAGE in cardiomyocytes","volume":"47","author":"Lee","year":"2017","journal-title":"Eur. J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0220","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mvr.2005.10.002","article-title":"Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension","volume":"70","author":"Nakamura","year":"2005","journal-title":"Microvasc. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0430","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/apha.12184","article-title":"Detrimental effects of acute hyperglycaemia on the rat heart","volume":"210","author":"Mapanga","year":"2014","journal-title":"Acta Physiol (Oxf.)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118538_b0435","first-page":"317","article-title":"Cardioprotective and antiapoptotic effects of aminoguanidine","volume":"76","author":"Dob\u0161\u00e1k","year":"2003","journal-title":"Scripta Medica Facultatis Medicae Universitatis Brunensis Masarykianae"},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0440","doi-asserted-by":"crossref","first-page":"E207","DOI":"10.1152\/ajpendo.00215.2010","article-title":"Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity","volume":"299","author":"Wang","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2026.118538_b0460","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1475-2840-12-5","article-title":"Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study","volume":"12","author":"Fukushima","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118538_b0465","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00380-015-0773-y","article-title":"Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)","volume":"31","author":"Shimomura","year":"2016","journal-title":"Heart Vessels"},{"issue":"6","key":"10.1016\/j.bcp.2026.118538_b0470","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1111\/1755-5922.12039","article-title":"Pyridoxamine reverts methylglyoxal-induced impairment of survival pathways during heart ischemia","volume":"31","author":"Almeida","year":"2013","journal-title":"Cardiovasc. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118538_b0340","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10495-015-1130-4","article-title":"A soluble receptor for advanced glycation end-products inhibits myocardial apoptosis induced by ischemia\/reperfusion via the JAK2\/STAT3 pathway","volume":"20","author":"Jiang","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.bcp.2026.118538_b0390","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.freeradbiomed.2016.02.011","article-title":"Soluble receptor for advanced glycation end-products protects against ischemia\/reperfusion-induced myocardial apoptosis via regulating the ubiquitin proteasome system","volume":"94","author":"Guo","year":"2016","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0510","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.yjmcc.2010.05.004","article-title":"High-mobility group box 1 (HMGB1) downregulates cardiac transient outward potassium current (Ito) through downregulation of Kv4.2 and Kv4.3 channel transcripts and proteins","volume":"49","author":"Liu","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0215","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s12272-014-0527-x","article-title":"Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction","volume":"38","author":"Ku","year":"2015","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0125","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1074\/jbc.M111.277731","article-title":"Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1","volume":"287","author":"Rai","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118538_b0130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neuint.2019.03.012","article-title":"The receptor for advanced glycation end products (RAGE) and DIAPH1: implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system","volume":"126","author":"MacLean","year":"2019","journal-title":"Neurochem. Int."},{"issue":"9","key":"10.1016\/j.bcp.2026.118538_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094579","article-title":"The RAGE\/DIAPH1 signaling axis & implications for the pathogenesis of diabetic complications","volume":"23","author":"Ramasamy","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118538_b0140","doi-asserted-by":"crossref","first-page":"22450","DOI":"10.1038\/srep22450","article-title":"Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction","volume":"6","author":"Manigrasso","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2026.118538_b0145","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.str.2016.06.021","article-title":"Change in the molecular dimension of a RAGE-ligand complex triggers RAGE signaling","volume":"24","author":"Xue","year":"2016","journal-title":"Structure (London, England: 1993)"},{"issue":"18","key":"10.1016\/j.bcp.2026.118538_b0150","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/cvr\/cvac175","article-title":"The RAGE\/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease","volume":"119","author":"Arivazhagan","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14789450.2017.1271719","article-title":"Glycation & the RAGE axis: targeting signal transduction through DIAPH1","volume":"14","author":"Shekhtman","year":"2017","journal-title":"Expert Rev. Proteomics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41467-020-20577-3","article-title":"Targeting adaptor protein SLP76 of RAGE as a therapeutic approach for lethal sepsis","volume":"12","author":"Yan","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1172\/JCI99987","article-title":"Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis","volume":"129","author":"Pickering","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.84969","article-title":"Interaction of \u03b21-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling","volume":"1","author":"Zhu","year":"2016","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.bcp.2026.118538_b0175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11739-009-0300-1","article-title":"Soluble forms of RAGE in internal medicine","volume":"4","author":"Vazzana","year":"2009","journal-title":"Intern. Emerg. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0169-328X(99)00174-6","article-title":"cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein","volume":"71","author":"Malherbe","year":"1999","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0185","first-page":"1","article-title":"Tissue-specific expression patterns of the RAGE receptor and its soluble forms\u2013a result of regulated alternative splicing?","volume":"1630","author":"Schlueter","year":"2003","journal-title":"BBA"},{"issue":"6220","key":"10.1016\/j.bcp.2026.118538_b0195","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science (New York, N.Y.)"},{"issue":"2\u20133","key":"10.1016\/j.bcp.2026.118538_b0200","first-page":"99","article-title":"The biology of the receptor for advanced glycation end products and its ligands","volume":"1498","author":"Schmidt","year":"2000","journal-title":"BBA"},{"key":"10.1016\/j.bcp.2026.118538_b0205","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2327341","article-title":"Expression of the receptor for advanced glycation end products in epicardial fat: link with tissue thickness and local insulin resistance in coronary artery disease","volume":"2016","author":"Dozio","year":"2016","journal-title":"J. Diabet. Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118538_b0210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1139\/cjpp-2015-0135","article-title":"Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis","volume":"94","author":"Khodeer","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118538_b0230","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2015.09.006","article-title":"RAGE siRNA-mediated gene silencing provides cardioprotection against ventricular arrhythmias in acute ischemia and reperfusion","volume":"217","author":"Park","year":"2015","journal-title":"J. Control. Release"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118538_b0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/10715762.2013.815348","article-title":"Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation","volume":"47","author":"Vistoli","year":"2013","journal-title":"Free Radic. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0240","article-title":"Cardioprotective effects of ferulic acid through inhibition of advanced glycation end products in diabetic rats with isoproterenol-induced myocardial infarction","volume":"18","author":"Bekheit","year":"2025","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/j.bcp.2026.118538_b0245","first-page":"207","article-title":"Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat","volume":"79","author":"Sun","year":"1998","journal-title":"Int. J. Exp. Pathol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118538_b0250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00395-017-0646-x","article-title":"Methylglyoxal-derived advanced glycation end products contribute to negative cardiac remodeling and dysfunction post-myocardial infarction","volume":"112","author":"Blackburn","year":"2017","journal-title":"Basic Res. Cardiol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118538_b0255","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1096\/fj.201900115RR","article-title":"Neutrophil-derived advanced glycation end products-N\u03b5-(carboxymethyl) lysine promotes RIP3-mediated myocardial necroptosis via RAGE and exacerbates myocardial ischemia\/reperfusion injury","volume":"33","author":"Yang","year":"2019","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.bcp.2026.118538_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010092","article-title":"RAGE modulates hypoxia\/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3\u03b2 signaling pathways","volume":"5","author":"Shang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118538_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105867","article-title":"Liraglutide protects against lethal renal ischemia-reperfusion injury by inhibiting high-mobility group box 1 nuclear-cytoplasmic translocation and release","volume":"173","author":"Li","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118538_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2024.112540","article-title":"Relationship between high-mobility group box-l and cognitive impairments induced by myocardial ischemia-reperfusion in elderly rats","volume":"195","author":"Yang","year":"2024","journal-title":"Exp. Gerontol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0280","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2008.12.016","article-title":"Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients","volume":"205","author":"Yan","year":"2009","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0285","doi-asserted-by":"crossref","first-page":"H422","DOI":"10.1152\/ajpheart.00249.2016","article-title":"Association of serum HMGB2 level with MACE at 1 mo of myocardial infarction: aggravation of myocardial ischemic injury in rats by HMGB2 via ROS, American journal of physiology","volume":"312","author":"Liu","year":"2017","journal-title":"Heart Circulat. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41065-025-00397-5","article-title":"Identification of regulator gene and pathway in myocardial ischemia-reperfusion injury: a bioinformatics and biological validation study","volume":"162","author":"Liu","year":"2025","journal-title":"Hereditas"},{"key":"10.1016\/j.bcp.2026.118538_b0295","article-title":"Engineered macrophage membrane-coated S100A9-siRNA for ameliorating myocardial ischemia-reperfusion injury","volume":"11","author":"Lu","year":"2024","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0300","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.atherosclerosis.2011.05.023","article-title":"Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury","volume":"217","author":"Cai","year":"2011","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0305","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCRESAHA.109.195834","article-title":"S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction","volume":"106","author":"Tsoporis","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2026.118538_b0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2019.05.020","article-title":"The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event","volume":"287","author":"Grauen Larsen","year":"2019","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.bcp.2026.118538_b0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415630","article-title":"A study on the protective effect of sRAGE-MSCs in a rodent reperfusion model of myocardial infarction","volume":"23","author":"Bayarsaikhan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118538_b0325","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.CIR.0000080378.96063.23","article-title":"Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0330","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.yjmcc.2011.08.015","article-title":"S100B-RAGE dependent VEGF secretion by cardiac myocytes induces myofibroblast proliferation","volume":"52","author":"Tsoporis","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0335","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1096\/fj.04-2780fje","article-title":"Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury","volume":"19","author":"Hwang","year":"2005","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0350","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1159\/000430388","article-title":"Autophagy plays a protective role in advanced glycation end product-induced apoptosis in cardiomyocytes","volume":"37","author":"Hu","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2026.118538_b0355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1475-2840-13-78","article-title":"Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE\/PI3K\/AKT\/mTOR pathway","volume":"13","author":"Hou","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2026.118538_b0365","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.freeradbiomed.2017.08.012","article-title":"Advanced glycation end products receptor RAGE controls myocardial dysfunction and oxidative stress in high-fat fed mice by sustaining mitochondrial dynamics and autophagy-lysosome pathway","volume":"112","author":"Yu","year":"2017","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0375","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcmg.2011.09.016","article-title":"Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury","volume":"5","author":"Tekabe","year":"2012","journal-title":"J. Am. Coll. Cardiol. Img."},{"issue":"26","key":"10.1016\/j.bcp.2026.118538_b0380","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1016\/j.biomaterials.2014.05.025","article-title":"Cardiac RNAi therapy using RAGE siRNA\/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction","volume":"35","author":"Hong","year":"2014","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.bcp.2026.118538_b0395","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132964","article-title":"Advanced glycation end products impair cardiac atrial appendage stem cells properties","volume":"10","author":"Evens","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118538_b0400","doi-asserted-by":"crossref","first-page":"149","DOI":"10.14283\/jpad.2018.18","article-title":"Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.bcp.2026.118538_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109165","article-title":"RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice","volume":"245","author":"Joshi","year":"2022","journal-title":"Clin. Immunol. (Orlando, Fla)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118538_b0410","article-title":"The RAGE inhibitor TTP488 (Azeliragon) improves diabetic bladder dysfunction in leptin-deficient obese mice","volume":"14","author":"Oliveira","year":"2025","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.bcp.2026.118538_b0415","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-14-12","article-title":"Effect of TTP488 in patients with mild to moderate Alzheimer\u2019s disease","volume":"14","author":"Burstein","year":"2014","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118538_b0420","doi-asserted-by":"crossref","DOI":"10.3390\/pathophysiology32030043","article-title":"Current evidence on the involvement of RAGE-Diaph1 signaling in the pathology and treatment of neurodegenerative diseases-an overview","volume":"32","author":"Juranek","year":"2025","journal-title":"Pathophysiology"},{"key":"10.1016\/j.bcp.2026.118538_b0425","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ebiom.2017.11.012","article-title":"The formin, DIAPH1, is a key modulator of myocardial ischemia\/reperfusion injury","volume":"26","author":"O'Shea","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0445","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am. J. Nephrol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118538_b0450","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0197-2456(99)00024-0","article-title":"Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)","volume":"20","author":"Freedman","year":"1999","journal-title":"Control. Clin. Trials"},{"issue":"4","key":"10.1016\/j.bcp.2026.118538_b0455","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10238-006-0115-6","article-title":"Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes","volume":"6","author":"Jinnouchi","year":"2006","journal-title":"Clin. Exp. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118538_b0475","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10719-016-9691-1","article-title":"Targeting advanced glycation with pharmaceutical agents: where are we now?","volume":"33","author":"Borg","year":"2016","journal-title":"Glycoconj. J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118538_b0480","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118538_b0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074302","article-title":"Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome","volume":"8","author":"Raposeiras-Roubin","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2026.118538_b0495","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MCA.0b013e32832c459c","article-title":"Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients","volume":"20","author":"Chiang","year":"2009","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.bcp.2026.118538_b0500","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijcard.2015.06.003","article-title":"Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease","volume":"197","author":"Yang","year":"2015","journal-title":"Int. J. Cardiol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:18:18Z","timestamp":1792052298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":102,"alternative-id":["S0006295226008804"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118538","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the RAGE signaling pathway in myocardial ischemia\/reperfusion injury","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118538"}}